[Dextran 40 for hypovolemia caused by hypertensive disease in pregnancy]

Dextran 40 was used in the management of hypovolemia and hemoconcentration in patients with hypertensive disease induced by pregnancy; 50 cases were randomly selected from a total of 150 patients from the Intensive Care Unit for Adults. The obstetrical profile, and perinatal profile, were determined. Hemodynamic and laboratory parameter, were statistically analyzed, before administration of Dextran 40 and at 2, 4, 6 and 8 hours after, and were compared. Eighty eight per cent of the selected cases corresponded to severe pre-eclampsia, and 12% to eclampsia; the age of the patients was 24 years; the number of gestations was 2.1 and they were at 32.6 weeks of gestation, average; eighty four percent were pregnant, and 16% were in puerperium at the moment of starting infusion; ninety per cent of the patients underwent cesarean section, and 10% were attended of a delivery. The products weighed 2,696 g; Apgar of 7.1 and 8.4 at fetal one and five minutes respectively, in average; there was one fetal death (2.4%), and one mortinate (2.4%); morbidity was 12%, and 85% of the products evolutionated satisfactorily. There were no maternal deaths. There was an statistically significant decrease is of BP after two hours, and a decrease of heart beat after four hours from starting infusion; as well as an increase in central venous pressure and diuresis, both after two hours from starting infusion of Dextran 40. There was a quantitative diminution of edema and proteinuria; as well as a quantitative diminution of hemoglobin, hematocrit, and fibrinogen after eight hours from starting infusion.(ABSTRACT TRUNCATED AT 250 WORDS)